A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma In Situ of the Bladder.
Li R, Sexton WJ, Dhillon J, Berglund A, Naidu S, Borjas G, Rose K, Kim Y, Wang X, Conejo-Garcia JR, Jain RK, Poch MA, Spiess PE, Pow-Sang J, Gilbert SM, Zhang J.
Li R, et al. Among authors: poch ma.
Clin Cancer Res. 2023 Oct 2;29(19):3875-3881. doi: 10.1158/1078-0432.CCR-23-0354.
Clin Cancer Res. 2023.
PMID: 37505486
Clinical Trial.